Average Co-Inventor Count = 4.12
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck + Co., Inc. (18 from 4,770 patents)
2. Merck Sharp + Dohme Corp. (16 from 2,405 patents)
3. Merck Canada Inc. (1 from 40 patents)
4. Merck Shapr & Dohme Corp. (1 from 1 patent)
5. Seynix, Inc. (1 from 1 patent)
6. Seynexis, Inc. (1 from 1 patent)
7. Scynexis, Inc. (18 patents)
8. Merck Sharp & Dohme LLC (6 patents)
36 patents:
1. 12304899 - Factor XI activation inhibitors
2. 10806724 - Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use
3. 10335399 - Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use
4. 10144741 - Nargenicin compounds and uses thereof as antibacterial agents
5. 10072003 - Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use
6. 9944654 - Nargenicin compounds and uses thereof as antibacterial agents
7. 9868733 - Azabenzimidazole tetrahydrofuran derivatives
8. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives
9. 9540364 - Benzimidazole tetrahydrofuran derivatives
10. 9527839 - Benzimidazole tetrahydropyran derivatives
11. 9382243 - Azabenzimidazole tetrahydropyran derivatives
12. 9290517 - Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
13. 8980929 - Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
14. 8853212 - Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
15. 8796258 - Cyclic azabenzimidazole derivatives useful as anti-diabetic agents